Fabien Hyafil, MD, PhD
Department of Nuclear Medicine
European Hospital Georges-Pompidou
Paris, France

Disclosures: Advisory Board: Naogen, Novo Nordisk; Consulting Fee: Naogen, Curium Pharma, Bracco Imaging, Blue Earth Diagnostics, Novo Nordisk

After participating in this activity, learners should be able to achieve the following:

• Describe characteristics of normal and abnormal FDG uptake on PET acquisitions in a suspicion of endocarditis.
• Identify characteristics of false positive studies.
• Explain the components of an appropriate report for FDG-PET acquisitions in patients with a suspicion of endocarditis (prosthetic valve endocarditis, native valve endocarditis, CIED).